within Pharmacolibrary.Drugs.N_NervousSystem.N07A_Parasympathomimetics.N07AX03_Cevimeline;
model Cevimeline 
   extends Pharmacolibrary.Drugs.ATC.N.N07AX03;

  annotation(Documentation(
    info ="<html><body><p>Cevimeline is a cholinergic agonist that selectively stimulates muscarinic M1 and M3 receptors, enhancing exocrine gland secretion, particularly saliva. It is primarily approved for the treatment of symptoms of dry mouth (xerostomia) associated with Sjögren’s syndrome. Cevimeline is an orally administered medication and remains in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following a single oral 30 mg dose.</p><h4>References</h4><ol><li><p>Weber, J, &amp; Keating, GM (2008). Cevimeline. <i>Drugs</i> 68(12) 1691–1698. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200868120-00006&quot;>10.2165/00003495-200868120-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18681491/&quot;>https://pubmed.ncbi.nlm.nih.gov/18681491</a></p></li><li><p>Tajiri, S, et al., &amp; Nakagami, H (2010). The relationship between the drug concentration profiles in plasma and the drug doses in the colon. <i>Chemical &amp; pharmaceutical bulletin</i> 58(10) 1295–1300. DOI:<a href=&quot;https://doi.org/10.1248/cpb.58.1295&quot;>10.1248/cpb.58.1295</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20930393/&quot;>https://pubmed.ncbi.nlm.nih.gov/20930393</a></p></li><li><p> (2000). Cevimeline (Evoxac) for dry mouth. <i>The Medical letter on drugs and therapeutics</i> 42(1084) 70–None. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10932302/&quot;>https://pubmed.ncbi.nlm.nih.gov/10932302</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Cevimeline;
